Organogenesis: 3 Key Takeaways for Long-Term Investors

Organogenesis reported Q3 2026 sequential revenue growth of 6% despite industry contraction from Medicare reimbursement policy changes. The company is benefiting from competitor exits and expects $45 million in annual operating expense reductions targeting Q4 profitability. However, the FDA extended the PDUFA target date for its Amnuvx knee osteoarthritis treatment beyond April 24, 2027, due to 18 manufacturing facility inspection items requiring remediation.